+41 91 682 20 40 info@elixi-int.com

Vyxeos (daunorubicin and cytarabine) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia

Jazz Pharmaceuticals plc has announced that the European Commission approved Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is an advanced liposomal formulation…

Read More
  • 1
  • 2